The Lancet Oncology (2018) 19(8):1014-1015
The fallout from the Cambridge Analytica–Facebook scandal marks a significant inflection point in the public’s trust concerning Big Data. The health-science community must use this crisis-in-confidence to redouble its commitment to talk openly and transparently about benefits and risks and to act decisively to deliver robust effective governance frameworks, under which personal health data can be responsibly used. Activities such as the Innovative Medicines Initiative’s Big Data for Better Outcomes emphasise how a more granular data-driven understanding of human diseases including cancer could underpin innovative therapeutic intervention. Health Data Research UK is developing national research expertise and infrastructure to maximise the value of health data science for the National Health Service and ultimately British citizens.
Director, HDR UK at Health Data Research UK (HDR UK)
Professor Andrew Morris became the inaugural Director of Health Data Research UK in August 2017. He is seconded from his position as Professor of Medicine, and Vice Principal of Data Science at...
Professor Mark Lawler
HDR UK Associate Director at Queens University Belfast
Mark is an internationally renowned scientist who has published over 200 papers including key publications in the highest impact journals (New Engl J Medicine, Lancet, Nature Medicine, Lancet...